JP2017527577A5 - - Google Patents

Download PDF

Info

Publication number
JP2017527577A5
JP2017527577A5 JP2017513208A JP2017513208A JP2017527577A5 JP 2017527577 A5 JP2017527577 A5 JP 2017527577A5 JP 2017513208 A JP2017513208 A JP 2017513208A JP 2017513208 A JP2017513208 A JP 2017513208A JP 2017527577 A5 JP2017527577 A5 JP 2017527577A5
Authority
JP
Japan
Prior art keywords
cancer
tumor
cell
alkyl
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017513208A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017527577A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/049219 external-priority patent/WO2016040504A1/en
Publication of JP2017527577A publication Critical patent/JP2017527577A/ja
Publication of JP2017527577A5 publication Critical patent/JP2017527577A5/ja
Pending legal-status Critical Current

Links

JP2017513208A 2014-09-10 2015-09-09 置換ピロリジン化合物 Pending JP2017527577A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462048757P 2014-09-10 2014-09-10
US62/048,757 2014-09-10
US201562146808P 2015-04-13 2015-04-13
US62/146,808 2015-04-13
PCT/US2015/049219 WO2016040504A1 (en) 2014-09-10 2015-09-09 Substituted pyrrolidine compounds

Publications (2)

Publication Number Publication Date
JP2017527577A JP2017527577A (ja) 2017-09-21
JP2017527577A5 true JP2017527577A5 (enExample) 2018-10-18

Family

ID=55459527

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017513208A Pending JP2017527577A (ja) 2014-09-10 2015-09-09 置換ピロリジン化合物

Country Status (6)

Country Link
US (2) US20170253601A1 (enExample)
EP (1) EP3193604B1 (enExample)
JP (1) JP2017527577A (enExample)
AU (1) AU2015315173A1 (enExample)
CA (1) CA2960273A1 (enExample)
WO (1) WO2016040504A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017526706A (ja) * 2014-09-10 2017-09-14 エピザイム,インコーポレイティド イソオキサゾールカルボキサミド化合物
AU2015315171A1 (en) 2014-09-10 2017-03-16 Epizyme, Inc. Substituted cyclohexylamine compounds
MX2017002986A (es) 2014-09-10 2017-10-24 Epizyme Inc Compuestos de piperidina sustituidos.
KR102496364B1 (ko) 2014-09-10 2023-02-06 에피자임, 인코포레이티드 Smyd 억제제
JP2017528460A (ja) 2014-09-10 2017-09-28 エピザイム インコーポレイテッド 不可逆的smyd阻害剤としてのイソオキサゾールカルボキサミド
WO2018151678A1 (en) * 2017-02-15 2018-08-23 Agency For Science, Technology And Research Compounds for treatment of cancer and epigenetics
MA51664B1 (fr) * 2018-01-26 2024-05-31 Idorsia Pharmaceuticals Ltd Formes cristallines de l'antagoniste du récepteur cxcr7 d'acide (3s,4s)-1-cyclopropylméthyl-4-([5-(2,4-difluoro-phényl)-isoxazole-3-carbonyl]-amino)-pipéridine-3-carboxylique (1-pyrimidin-2-yl-cyclopropyl)-amide
EP3986886A2 (en) 2019-06-19 2022-04-27 Grünenthal GmbH Substituted pyrrolidine amides v
WO2025133989A1 (en) * 2023-12-20 2025-06-26 Alt-Bio Pte. Ltd. Smyd modulators and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1287434A (en) * 1918-05-16 1918-12-10 Waterbury Mfg Co Combined shade-holder and socket-cover.
AR060607A1 (es) * 2006-04-21 2008-07-02 Novartis Ag Derivados de purina,composiciones farmaceuticas que los contienen, metodo de preparacion y usos en enfermedades obstructivas o inflamatorias de las vias respiratorias.
CA2657078A1 (en) * 2006-07-13 2008-01-17 High Point Pharmaceuticals, Llc 11beta-hydroxysteroid dehydrogenase type 1 active compounds
WO2014175370A1 (ja) * 2013-04-25 2014-10-30 塩野義製薬株式会社 ピロリジン誘導体およびそれらを含有する医薬組成物

Similar Documents

Publication Publication Date Title
JP2017527577A5 (enExample)
JP2017528464A5 (enExample)
JP2017538659A5 (enExample)
JP2017526706A5 (enExample)
JP2016514695A5 (enExample)
JP2019514950A5 (enExample)
CA2807620C (en) Pharmaceutically active compounds as axl inhibitors
Chen et al. Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl) phenyl) amino) pyrimidin-2-yl) amino)-4-methoxy-2-(4-methyl-1, 4-diazepan-1-yl) phenyl) acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC
JP2017528460A5 (enExample)
EA201391319A1 (ru) Способ лечения рака с использованием 3-(5-амино-2-метил-4-оксо-4h-хиназолин-3-ил)пиперидин-2,6-диона
RU2013148728A (ru) Комбинации соединений, ингибирующих акт, и эрлотиниба и способы их применения
JP2017537946A5 (enExample)
JP2020515571A5 (enExample)
WO2008089388A3 (en) Treatment of cancers having resistance to chemotherapeutic agents
JP2011515397A5 (enExample)
MX367869B (es) Metodos de tratamiento de cancer usando 3-(4((4-(morfolinometil) bencil) oxi)-1-oxoisoindolin-2-il) piperidin-2, 6-diona.
PH12015501326A1 (en) 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
JP2017527576A5 (enExample)
JP2004525965A5 (enExample)
MY167423A (en) Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators,compositions,and their use
JP2014520808A (ja) Hsp90阻害化合物を用いた癌の治療
CN105120868A (zh) 组合治疗
TWI366671B (en) Selection of colorectal cancer patients for treatment with drugs targeting egfr pathway
NZ598758A (en) N-4 (-((3-(2-amino-4 pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer
EA201270205A1 (ru) Фармацевтические композиции для лечения рака и других заболеваний и нарушений состояния здоровья